Pathology in permissive syrian hamsters after infection with species C human adenovirus (HAdV-C) is the result of virus replication: HAdV-C6 replicates more and causes more pathology than HAdV-C5

Journal of Virology

Volumn 91, Issue 10, 2017, Pages

  Tollefson, Ann E ^a   Ying, Baoling ^a   Spencer, Jacqueline F ^a   Sagartz, John E ^a   Wold, William S M ^a   Toth, Karoly ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenoviruses; Hamster; Viral pathogenesis

Indexed keywords

ALANINE AMINOTRANSFERASE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN ADENOVIRUS 5; HUMAN ADENOVIRUS C; HUMAN ADENOVIRUS C6; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KUPFFER CELL; LIVER CELL; NONHUMAN; PLAQUE ASSAY; PRIORITY JOURNAL; SYRIAN HAMSTER; TISSUE CULTURE INFECTIOUS DOSE ASSAY; VIRUS INFECTION; VIRUS REPLICATION; ANIMAL; CELL LINE; CLASSIFICATION; DISEASE MODEL; HAMSTER; HUMAN ADENOVIRUS INFECTION; KIDNEY; LIVER; LUNG; MACROPHAGE; MESOCRICETUS; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS LOAD;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; CELL LINE; CRICETINAE; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY; KUPFFER CELLS; LIVER; LUNG; MACROPHAGES; MESOCRICETUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 85018281045     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00284-17     Document Type: Article

References (59)

1. Berk AJ. 2013. Adenoviridae, p 1704-1731. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Wold WSM, Ison MG. 2013. Adenoviruses, p 1732. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Walsh MP, Seto J, Liu EB, Dehghan S, Hudson NR, Lukashev AN, Ivanova O, Chodosh J, Dyer D, Jones MS, Seto D. 2011. Computational analysis of two species C human adenoviruses provides evidence of a novel virus. J Clin Microbiol 49:3482-3490. https://doi.org/10.1128/JCM.00156-11.
4. Ginsberg HS, Lundholm-Beauchamp U, Horswood RL, Pernis B, Wold WSM, Chanock RM, Prince GA. 1989. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci U S A 86:3823-3827. https://doi.org/ 10.1073/pnas.86.10.3823.
5. Hjorth RN, Bonde GM, Pierzchala WA, Vernon SK, Wiener FP, Levner MH, Lubeck MD, Hung PP. 1988. A new hamster model for adenoviral vaccination. Arch Virol 100:279-283. https://doi.org/10.1007/BF01487691.
6. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS. 2006. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 66:1270-1276. https://doi.org/10.1158/0008-5472.CAN-05-3497.
7. Pacini DL, Dubovi EJ, Clyde WA, Jr. 1984. A new animal model for human respiratory tract disease due to adenovirus. J Infect Dis 150:92-97. https://doi.org/10.1093/infdis/150.1.92.
8. Toth K, Spencer JF, Tollefson AE, Kuppuswamy M, Doronin K, Lichtenstein DL, La Regina MC, Prince GA, Wold WSM. 2005. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 16:139-146. https://doi.org/10.1089/hum.2005.16.139.
9. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips N, Wold WSM. 2008. Immunosuppression enhances oncolytic adenovirus replication and anti tumor efficacy in the Syrian hamster model. Mol Ther 16:1665-1673. https://doi.org/10.1038/mt.2008.162.
10. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer J, Shashkova EV, Kuppuswamy M, Dhar D, Thomas MA, Tollefson AE, Zumstein LA, Wold WSM, Toth K. 2009. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replicationdefective adenovirus vector. Cancer Gene Ther 16:644-654. https:// doi.org/10.1038/cgt.2009.5.
11. Shashkova EV, Spencer JF, Wold WSM, Doronin K. 2007. Targeting interferon-γ increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther 15: 598-607. https://doi.org/10.1038/sj.mt.6300064.
12. Spencer JF, Sagartz JE, Wold WSM, Toth K. 2009. New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther 16:912-922. https://doi.org/10.1038/ cgt.2009.36.
13. Dhar D, Spencer JF, Toth K, Wold WSM. 2009. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther 17: 1724-1732. https://doi.org/10.1038/mt.2009.156.
14. Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WS. 2013. The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. Cancer Gene Ther 20:521-530. https://doi.org/10.1038/cgt.2013.49.
15. Young BA, Spencer JF, Ying B, Toth K, Wold WS. 2013. The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model. Cancer Gene Ther 20:531-537. https://doi.org/10 .1038/cgt.2013.50.
16. Dhar D, Toth K, Wold WS. 2014. Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters. Cancer Gene Ther 21:171-178. https://doi.org/10.1038/cgt.2014.13.
17. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, Dhar D, Shashkova EV, Kuppuswamy M, Doronin K, Thomas MA, Zumstein LA, Wold WS, Lichtenstein DL. 2009. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 16:625-637. https://doi.org/10 .1038/cgt.2009.6.
18. Bortolanza S, Alzuguren P, Bunuales M, Qian C, Prieto J, Hernandez-Alcoceba R. 2007. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 18: 681-690. https://doi.org/10.1089/hum.2007.017.
19. Sonabend AM, Ulasov IV, Han Y, Rolle CE, Nandi S, Cao D, Tyler MA, Lesniak MS. 2009. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther 16:362-372. https://doi.org/ 10.1038/cgt.2008.80.
20. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Sarkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimaki A, Raisanen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A. 2010. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 70:4297-4309. https:// doi.org/10.1158/0008-5472.CAN-09-3567.
21. Kim KH, Ryan MJ, Estep JE, Miniard BM, Rudge TL, Peggins JO, Broadt TL, Wang M, Preuss MA, Siegal GP, Hemminki A, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. 2011. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-delta24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther 22:821-828. https://doi.org/10.1089/ hum.2010.180.
22. Bortolanza S, Bunuales M, Otano I, Gonzalez-Aseguinolaza G, Ortiz-de-Solorzano C, Perez D, Prieto J, Hernandez-Alcoceba R. 2009. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther 17:614-622. https://doi.org/ 10.1038/mt.2009.9.
23. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Joensuu T, Kanerva A, Hemminki A. 2010. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 18:1874-1884. https://doi.org/ 10.1038/mt.2010.161.
24. Bortolanza S, Bunuales M, Alzuguren P, Lamas O, Aldabe R, Prieto J, Hernandez-Alcoceba R. 2009. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. Cancer Gene Ther 16:703-712. https://doi.org/ 10.1038/cgt.2009.12.
25. Hasegawa N, Abei M, Yokoyama KK, Fukuda K, Seo E, Kawashima R, Nakano Y, Yamada T, Nakade K, Hamada H, Obata Y, Hyodo I. 2013. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Int J Cancer 133:1479-1488. https://doi.org/10 .1002/ijc.28132.
26. Bunuales M, Garcia-Aragoncillo E, Casado R, Quetglas JI, Hervas-Stubbs S, Bortolanza S, Benavides-Vallve C, Ortiz-de-Solorzano C, Prieto J, Hernandez-Alcoceba R. 2012. Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer. Hum Gene Ther 23:1258-1268. https://doi.org/ 10.1089/hum.2012.043.
27. LaRocca CJ, Han J, Gavrikova T, Armstrong L, Oliveira AR, Shanley R, Vickers SM, Yamamoto M, Davydova J. 2015. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery 157:888-898. https://doi.org/ 10.1016/j.surg.2015.01.006.
28. Nguyen TV, Heller GJ, Barry ME, Crosby CM, Turner MA, Barry MA. 2016. Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers. Mol Ther Oncolytics 3:15021. https://doi.org/10.1038/mto.2015.21.
29. Wold WS, Toth K. 2012. Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res 115:69-92. https://doi.org/10.1016/B978-0-12-398342-8.00003-3.
30. Dhar D, Toth K, Wold WS. 2012. Syrian hamster tumor model to study oncolytic Ad5-based vectors. Methods Mol Biol 797:53-63. https://doi .org/10.1007/978-1-61779-340-0_4.
31. Toth K, Lee SR, Ying B, Spencer JF, Tollefson AE, Sagartz JE, Kong IK, Wang Z, Wold WS. 2015. STAT2 knockout Syrian hamsters support enhanced replication and pathogenicity of human adenovirus, revealing an important role of type I interferon response in viral control. PLoS Pathog 11:e1005084. https://doi.org/10.1371/journal.ppat.1005084.
32. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR, Wold WSM. 2008. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirusinduced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A 105:7293-7297. https://doi.org/10.1073/pnas .0800200105.
33. Tollefson AE, Spencer JF, Ying B, Buller RM, Wold WS, Toth K. 2014. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model. Antiviral Res 112:38-46. https://doi.org/10.1016/j.antiviral.2014.10.005.
34. Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Dewhurst S, Capella C, Buller RM, Toth K, Wold WS. 2014. Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters. Antimicrob Agents Chemother 58:7171-7181. https://doi.org/ 10.1128/AAC.03860-14.
35. Toth K, Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Sagartz JE, Buller RM, Wold WS. 2015. Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters. Viruses 7:1409-1428. https://doi.org/10 .3390/v7031409.
36. Ying B, Toth K, Spencer JF, Aurora R, Wold WSM. 2015. Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters. Virology 485:305-312. https://doi.org/10.1016/j.virol.2015.07.024.
37. Tchitchek N, Safronetz D, Rasmussen AL, Martens C, Virtaneva K, Porcella SF, Feldmann H, Ebihara H, Katze MG. 2014. Sequencing, annotation and analysis of the Syrian hamster (Mesocricetus auratus) transcriptome. PLoS One 9:e112617. https://doi.org/10.1371/journal.pone.0112617.
38. Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, Fu TM, Bett A, Colloca S, Cortese R, Nicosia A, Folgori A. 2006. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 80:1688-1699. https://doi.org/10.1128/JVI .80.4.1688-1699.2006.
39. Chen CY, Weaver EA, Khare R, May SM, Barry MA. 2011. Mining the adenovirus virome for oncolytics against multiple solid tumor types. Cancer Gene Ther 18:744-750. https://doi.org/10.1038/cgt.2011.47.
40. Crosby CM, Nehete P, Sastry KJ, Barry MA. 2015. Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J Virol 89:669-675. https://doi.org/10.1128/JVI.02184-14.
41. Shashkova EV, May SM, Barry MA. 2009. Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology 394:311-320. https://doi.org/10.1016/j.virol.2009.08.038.
42. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW. 2010. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28:950-957. https:// doi.org/10.1016/j.vaccine.2009.10.145.
43. Wolff G, Worgall S, vanRooijen N, Song WR, Harvey BG, Crystal RG. 1997. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 71:624-629.
44. Alemany R, Balague C, Curiel DT. 2000. Replicative adenoviruses for cancer therapy. Nat Biotechnol 18:723-727. https://doi.org/10.1038/ 77283.
45. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 8:37-77. https://doi.org/10.1089/ hum.1997.8.1-37.
46. Khare R, May SM, Vetrini F, Weaver EA, Palmer D, Rosewell A, Grove N, Ng P, Barry MA. 2011. Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther 19:1254-1262. https://doi.org/10.1038/mt.2011.71.
47. Khare R, Hillestad ML, Xu Z, Byrnes AP, Barry MA. 2013. Circulating antibodies and macrophages as modulators of adenovirus pharmacology. J Virol 87:3678-3686. https://doi.org/10.1128/JVI.01392-12.
48. Weaver EA, Hillestad ML, Khare R, Palmer D, Ng P, Barry MA. 2011. Characterization of species C human adenovirus serotype 6 (Ad6). Virology 412:19-27. https://doi.org/10.1016/j.virol.2010.10.041.
49. Turner MA, Middha S, Hofherr SE, Barry MA. 2015. Comparison of the life cycles of genetically distant species C and species D human adenoviruses Ad6 and Ad26 in human cells. J Virol 89:12401-12417. https://doi .org/10.1128/JVI.01534-15.
50. Alemany R, Suzuki K, Curiel DT. 2000. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81:2605-2609. https://doi.org/10.1099/ 0022-1317-81-11-2605.
51. Ganesan LP, Mohanty S, Kim J, Clark KR, Robinson JM, Anderson CL. 2011. Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathog 7:e1002281. https://doi.org/10.1371/ journal.ppat.1002281.
52. Piccolo P, Annunziata P, Mithbaokar P, Brunetti-Pierri N. 2014. SR-A and SREC-I binding peptides increase HDAd-mediated liver transduction. Gene Ther 21:950-957. https://doi.org/10.1038/gt.2014.71.
53. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE. 2001. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3:28-35. https://doi.org/10.1006/mthe.2000.0227.
54. Alzuguren P, Hervas-Stubbs S, Gonzalez-Aseguinolaza G, Poutou J, Fortes P, Mancheno U, Bunuales M, Olague C, Razquin N, Van Rooijen N, Enguita M, Hernandez-Alcoceba R. 2015. Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver. Liver Int 35:1274-1289. https://doi.org/10.1111/ liv.12571.
55. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA. 1997. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71:8798-8807.
56. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. 2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148-158. https://doi.org/10.1016/j.ymgme .2003.08.016.
57. Sitia G, Iannacone M, Aiolfi R, Isogawa M, van Rooijen N, Scozzesi C, Bianchi ME, von Andrian UH, Chisari FV, Guidotti LG. 2011. Kupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitis. PLoS Pathog 7:e1002061. https://doi.org/10.1371/journal.ppat .1002061.
58. Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WS. 2007. Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol Med 130:223-235.
59. Thomas MA, Spencer JF, Wold WSM. 2007. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 130:169-183. https://doi.org/10.1385/1-59745-166-5:169.